Algernon Pharmaceuticals appoints Sandor Nardai as OI for Phase 2a DMT study
Algernon NeuroScience has appointed Dr. Sandor Nardai as the Principal Investigator for its upcoming randomized, double-blind, placebo-controlled Phase 2a DMT study of 40 stroke patients in Europe.
‘I’m just a seeker’: The Sydney mum who spent a year sampling psychedelics
Sarah Napthali lowers her voice over lunch when our conversation veers to the names of the drugs she used: LSD, MDMA, ...
What is ayahuasca? Netflix's Apple Cider Vinegar explores psychedelic retreats
The psychedelic drug is increasingly popular and is also frequently referenced in pop culture – including Netflix's new drama ...
Algernon Pharmaceuticals appoints Validcare as CRO for Phase 2a DMT trial
Algernon Pharmaceuticals (AGNPF) announced that its wholly owned subsidiary, Algernon NeuroScience, has appointed Validcare as the contract ...
Hosted on MSN16d
Speed and Power training for athletes
I Asked 4 Chefs for the Best Cold Sub Chain, and There Was a Clear Favorite The Federal Reserve may try something new: Pausing Black Panther Recast Update, Captain America 4 Official News & New ...
Investing24d
Australia's Liontown shares jump on robust quarterly production, sales
Liontown posted a 215% quarter-on-quarter increase in spodumene production, reaching 88,683 dry metric tonnes (dmt) for the quarter ended December 31. Liontown's sales also surged, with 81,341 dmt ...
The Vancouver Sun24d
Battle brews over B.C. civil forfeiture after Vancouver drug activist targeted
adding that the stores sold psilocybin mushrooms, coca leaf, lysergic acid diethylamide (LSD), and dimethyltryptamine (DMT).